DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Vitiligo Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Vitiligo, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Vitiligo Market
The market size for Vitiligo in the leading markets is expected to grow significantly by 2036.
The 7MM Vitiligo market is projected to increase from approximately USD 1.0 billion in 2022 to nearly USD 4.1 billion by 2036, reflecting substantial growth during the forecast period.
According to DelveInsight’s estimates, the diagnosed patient pool in the 7MM is expected to increase from approximately 6.9 million cases in 2022 to nearly 9.6 million cases by 2036.
Based on DelveInsight’s assessment, the total prevalent cases of vitiligo in the 7MM were approximately 12 million in 2025.
In 2025, the United States accounted for approximately 45% of the total vitiligo patient population across the 7MM, followed by EU4 and the United Kingdom (approximately 50%), while Japan represented around 5% of total cases.
In 2025, non-segmental vitiligo accounted for approximately 9 million cases, whereas segmental vitiligo represented approximately 2.8 million cases across the 7MM.
Females accounted for approximately 60% of vitiligo cases in the 7MM during 2025, while males represented approximately 40% of the patient population.
OPZELURA (ruxolitinib cream) is the first and only FDA-approved treatment specifically indicated for non-segmental vitiligo in patients aged 12 years and older, representing a significant advancement in targeted immunotherapy.
Leading Vitiligo companies, including Incyte Corporation, AbbVie, Pfizer, CLINUVEL, VYNE Therapeutics, and others, are actively developing innovative therapies expected to transform the Vitiligo treatment landscape over the coming years.
Promising Vitiligo therapies in clinical development include RINVOQ (upadacitinib), LITFULO (ritlecitinib), Povorcitinib, SCENESSE (afamelanotide), and Repibresib (VYN201).
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/vitiligo-market
Key Factors Driving the Vitiligo Market
Growing Disease Awareness and Improved Diagnosis
Increasing awareness regarding vitiligo as an autoimmune skin disorder, improved access to dermatology specialists, and enhanced diagnostic capabilities are contributing to higher diagnosis rates and earlier treatment initiation. Growing recognition of the psychological burden associated with vitiligo is also encouraging patients to seek medical care.
Expansion of Targeted JAK Inhibitor Therapies
The approval of OPZELURA (ruxolitinib cream) has significantly transformed the treatment landscape for non-segmental vitiligo by introducing targeted immunotherapy. The anticipated launch of additional JAK inhibitors, including RINVOQ, LITFULO, and Povorcitinib, is expected to further expand therapeutic options and improve treatment outcomes.
Robust Pipeline of Emerging Immunomodulatory Therapies
The Vitiligo pipeline continues to expand with innovative therapies targeting multiple immune pathways and melanocyte stimulation mechanisms. The advancement of oral, topical, and implantable therapies is expected to improve repigmentation outcomes, broaden treatment accessibility, and drive substantial market growth during the forecast period.
Vitiligo Competitive Landscape
The Vitiligo treatment landscape has evolved significantly following the approval of OPZELURA (ruxolitinib cream), the first targeted therapy specifically approved for non-segmental vitiligo. Current treatment approaches also include topical corticosteroids, topical calcineurin inhibitors, vitamin D analogs, phototherapy, and surgical interventions for selected patients. While these therapies can restore pigmentation in many patients, treatment responses remain variable, highlighting the continued need for more effective long-term therapeutic options.
The competitive landscape is rapidly evolving with multiple late-stage pipeline candidates targeting the underlying autoimmune mechanisms of vitiligo. RINVOQ (upadacitinib), LITFULO (ritlecitinib), and Povorcitinib are advancing as oral JAK inhibitors, while SCENESSE (afamelanotide) targets melanocortin receptor pathways to promote repigmentation. Repibresib (VYN201) is also being investigated as a novel topical therapeutic approach. These emerging therapies are expected to significantly reshape the Vitiligo treatment landscape over the forecast period.
Discover more about therapies set to grab major Vitiligo market share @ Vitiligo Treatment Landscape
Recent Developments in the Vitiligo Market
In February 2026, AbbVie submitted regulatory applications to the US FDA and the European Medicines Agency (EMA) seeking approval of RINVOQ (upadacitinib) for the treatment of adults and adolescents with vitiligo.
In October 2025, AbbVie announced positive Phase III topline results demonstrating the efficacy and safety of RINVOQ (upadacitinib) in adults and adolescents with vitiligo.
In September 2025, CLINUVEL presented new clinical data at the European Academy of Dermatology and Venereology (EADV) Congress in Paris demonstrating the efficacy of SCENESSE (afamelanotide) in patients with vitiligo.
In July 2025, VYNE Therapeutics reported topline results from its Phase IIb study evaluating Repibresib (VYN201) in patients with non-segmental vitiligo. Although the trial did not meet its primary or key secondary endpoints, the company announced plans to seek an external partner for continued development.
In January 2025, CLINUVEL shared initial observations from the randomized CUV105 clinical study evaluating SCENESSE (afamelanotide) for the treatment of vitiligo.
What is Vitiligo?
Vitiligo is a chronic autoimmune depigmenting skin disorder characterized by the selective destruction of melanocytes, the pigment-producing cells responsible for skin color. The disease results in well-defined depigmented white patches that may appear on any part of the body, including the face, hands, arms, feet, mucous membranes, and hair-bearing areas. Although vitiligo is not physically life-threatening, it can significantly impair patients’ psychological well-being, self-esteem, and quality of life due to its visible nature.
Vitiligo is broadly classified into non-segmental vitiligo (NSV), segmental vitiligo (SV), and mixed vitiligo, with non-segmental vitiligo representing the most common clinical subtype. Diagnosis is primarily based on clinical examination and may be supported by Wood’s lamp examination, skin biopsy, and laboratory evaluation for associated autoimmune disorders. Current treatment strategies include topical corticosteroids, topical calcineurin inhibitors, phototherapy, surgical procedures, and targeted JAK inhibitor therapy, with ongoing research focused on developing disease-modifying immunotherapies capable of achieving sustained repigmentation.
Vitiligo Epidemiology Segmentation
The Vitiligo epidemiology section provides insights into the historical and current Vitiligo patient pool and forecasted trends across the seven major markets. The Vitiligo market report provides epidemiological analysis for the study period 2022–2036, segmented into:
Total Prevalent Cases of Vitiligo
Total Diagnosed Prevalent Cases of Vitiligo
Gender-specific Cases of Vitiligo
Type-specific Cases of Vitiligo
Age-specific Cases of Vitiligo
Total Treated Cases of Vitiligo
Scope of the Vitiligo Market Report
Therapeutic Assessment: Current marketed and emerging therapies for Vitiligo
Vitiligo Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, and market outlook
Key Companies: Incyte Corporation, AbbVie, Pfizer, CLINUVEL, VYNE Therapeutics, and others
Key Therapies: OPZELURA (ruxolitinib), RINVOQ (upadacitinib), LITFULO (ritlecitinib), Povorcitinib, SCENESSE (afamelanotide), Repibresib (VYN201), topical corticosteroids, topical calcineurin inhibitors, Vitamin D topical cream, and others
Competitive Intelligence Analysis: SWOT analysis and Market Entry Strategies
Unmet Needs, KOL’s Views, Analyst’s Views, Vitiligo Market Access and Reimbursement
To know more about Vitiligo companies working in the treatment market, visit @ Vitiligo Clinical Trials and Therapeutic Assessment
Table of Contents
Vitiligo Market Report Introduction
Executive Summary for Vitiligo
SWOT Analysis of Vitiligo
Vitiligo Patient Share (%) Overview at a Glance
Vitiligo Market Overview at a Glance
Vitiligo Background and Overview
Vitiligo Epidemiology and Patient Population
Country-Specific Patient Population of Vitiligo
Vitiligo Current Treatment and Medical Practices
Vitiligo Unmet Needs
Vitiligo Emerging Therapies
Vitiligo Market Outlook
Country-Wise Vitiligo Market Analysis (2022–2036)
Vitiligo Market Access and Reimbursement of Therapies
Vitiligo Market Drivers
Vitiligo Market Barriers
Vitiligo Appendix
Vitiligo Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
